Seeking Alpha

Nektar Therapeutics (NKTR) agrees to sell royalties for its Cimzia and Mircera drugs to Royalty...

Nektar Therapeutics (NKTR) agrees to sell royalties for its Cimzia and Mircera drugs to Royalty Pharma for $124M. The company plans to use the net proceeds of the transaction towards the repayment of its $215M in convertible debt. Shares are currently under a trading halt.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|